Forian Inc. Reports Strong Revenue Growth Amid Strategic Investments and Potential Acquisition Discussions

Forian Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, showcasing substantial revenue growth alongside strategic investments that impacted profitability metrics. The company, a provider of data science driven information and analytics solutions, achieved full-year revenue of $30.3 million, representing a 50% increase from the prior year. Fourth quarter revenue reached $8.0 million, a 37% increase year-over-year. However, the company reported a net loss of $1.8 million for the quarter, compared to net income of $0.2 million in the prior year period, and a full-year net loss of $2.9 million, an improvement from a $3.8 million loss in 2024.

Chief Executive Officer Max Wygod stated the company demonstrated that disciplined cost management and strategic investment can coexist. The period was marked by business growth, expansion into new markets, and targeted investments in the data platform and product development. A key performance indicator, Adjusted EBITDA, was $0.8 million for the full year, a 72% increase, though it was negative $0.2 million for the fourth quarter. The company ended the year with $31.6 million in cash, cash equivalents, and marketable securities.

Corporate developments included a notable update on a potential acquisition. On August 25, 2025, a consortium led by Forian’s Chief Executive Officer and Executive Chair submitted a non-binding proposal to acquire all outstanding shares not currently owned by the consortium. A Special Committee formed to evaluate this proposal remains in place and is in discussions with the consortium. The company noted there can be no assurance that any transaction will result from these discussions. For more details on the company's financials and operations, investors can visit https://www.forian.com.

The financial results underscore a year of significant transition and investment for Forian. Full-year highlights included achieving revenue guidance, delivering on Adjusted EBITDA margin targets, and strengthening the data platform through expanded contracting and new clinical data feeds. The company also reported growing its pharmaceutical and biotech customer footprint. The increased costs and expenses, particularly in research and development, sales and marketing, and strategic review activities, contributed to the net losses despite strong top-line growth. The reconciliation of U.S. GAAP to non-GAAP financial measures, detailed in the release, shows adjustments for items like stock-based compensation, depreciation, and transaction-related expenses.

The implications of these results are multifaceted. The robust revenue growth of 50% for the year signals strong market demand for Forian's data and analytics offerings in the life sciences and healthcare sectors. This expansion, however, comes at a cost, as evidenced by the net losses, which the company attributes to strategic investments aimed at long-term growth. The concurrent discussion of a potential management-led buyout introduces a significant element of uncertainty regarding the company's future ownership structure and strategic direction. The combination of rapid growth, continued investment, and corporate development activity positions Forian at a critical juncture, balancing operational execution with potential transformative corporate action.